GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: DCC-2618 | DCC2618 | Quinlock®
                                 
                                                         
                            
                            
                            
                                 
                                
                                ripretinib is an approved drug (FDA (2020), EMA (2021)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor that was developed by Dicephera Pharmaceuticals.  It was designed for the treatment of  malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors [1]. Another example of a switch control inhibitor is avapritinib.   
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                    The chemical structure shown here matches that supplied to the WHO for the INN, and this is claimed in patent WO2010051373 [2] as Example 39. Note that some PubChem SIDs are linked to an incorrect structure (as represented in PubChem CID 46208890).  | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
Download 2D Structure ![]()  | 
                                                        |
| Canonical SMILES | Download | 
| Isomeric SMILES | Download | 
| InChI standard identifier | Download | 
| InChI standard key | Download | 
Molecular structure representations generated using Open Babel